Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Cash from Financing Activities for 12 consecutive years, with $7.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 751.4% year-over-year to $7.9 million; the TTM value through Mar 2026 reached $20.7 million, down 94.13%, while the annual FY2025 figure was $13.7 million, 96.13% down from the prior year.
  • Cash from Financing Activities hit $7.9 million in Q1 2026 for Syndax Pharmaceuticals, up from $5.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $347.4 million in Q4 2024 and bottomed at -$13.5 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $47.7 million, with a median of $2.5 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities crashed 893.26% in 2022 and then surged 751.4% in 2026.
  • Syndax Pharmaceuticals' Cash from Financing Activities stood at $163.5 million in 2022, then skyrocketed by 58.09% to $258.5 million in 2023, then surged by 34.41% to $347.4 million in 2024, then plummeted by 98.3% to $5.9 million in 2025, then soared by 33.82% to $7.9 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $7.9 million, $5.9 million, and $6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.